期刊
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
卷 23, 期 4, 页码 465-472出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcdb.2012.01.016
关键词
Notch; Cancer; T-ALL; gamma-Secretase; Inhibitor
资金
- NIH from National Institute of General Medical Sciences (NIGMS) [R01 GM087650]
- Thomas Jefferson University Department of Biochemistry
Dysregulated Notch signaling has been implicated in numerous human diseases, including a broad spectrum of cancers. Mutations in Notch1 are prevalent in T-cell acute lymphoblastic leukemia, and abnormal expression of different human Notch receptors contributes to B-cell tumors as well as cancers of the breast, lung, pancreas, skin, prostate, colon, brain and other tissues. Several gamma-secretase inhibitors, small chemical compounds that were initially developed to inhibit the activity of the gamma-secretase aspartyl protease in Alzheimer's disease, are now being explored for their potential chemotherapeutic applications in Notch-associated cancers. An alternative approach involves the development of antibodies to inhibit specific Notch receptors, their activating ligands, or other components of the Notch pathway in tumors. Here we review recent progress and current challenges in the use of these strategies to modulate Notch signaling for cancer therapy. (C) 2012 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据